On Nov 01, major Wall Street analysts update their ratings for $Madrigal Pharmaceuticals (MDGL.US)$, with price targets ranging from $350 to $441.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $410 to $441.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $390.
Oppenheimer analyst Jay Olson maintains with a buy rating, and maintains the target price at $350.
CCORF analyst Edward Nash maintains with a buy rating, and adjusts the target price from $377 to $394.
Furthermore, according to the comprehensive report, the opinions of $Madrigal Pharmaceuticals (MDGL.US)$'s main analysts recently are as follows:
Madrigal Pharmaceuticals' notable outperformance in Q3 with Rezdiffra underscores an undervalued potential in the nonalcoholic steatohepatitis market. The upcoming ESSENCE event may further provide a decisive moment, according to an analyst's research note.
Here are the latest investment ratings and price targets for $Madrigal Pharmaceuticals (MDGL.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
